Eddie Yan Selected Research

squaramide

1/2021	Imaging Somatostatin Positive Tumors with Tyr3-Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68.
10/2020	Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eddie Yan Research Topics

Disease

3	Neoplasms (Cancer) 05/2022 - 10/2020
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2022
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2021
1	Prostatic Neoplasms (Prostate Cancer) 10/2020

Drug/Important Bio-Agent (IBA)

2	Radioisotopes (Radionuclides)IBA 05/2022 - 01/2021
2	squaramideIBA 01/2021 - 10/2020
2	Deferoxamine (Desferal)FDA LinkGeneric 01/2021 - 10/2020
2	Zirconium-89IBA 01/2021 - 10/2020
2	Gallium-68IBA 01/2021 - 10/2020
1	Lutetium-177IBA 05/2022
1	Actinium-225IBA 05/2022
1	Carbonic Anhydrase IXIBA 05/2022
1	Immunoconjugates (Immunoconjugate)IBA 05/2022
1	Peptide Hormones (Polypeptide Hormones)IBA 01/2021
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2021
1	Octreotide (Sandostatin)FDA LinkGeneric 01/2021
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2021
1	CarboxypeptidasesIBA 10/2020
1	LigandsIBA 10/2020
1	AntigensIBA 10/2020

Therapy/Procedure

2	Therapeutics 05/2022 - 10/2020